{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:59:42Z","timestamp":1762865982454,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011284","name":"Valeant Pharmaceuticals International","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011284","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.eplepsyres.2012.05.007","type":"journal-article","created":{"date-parts":[[2012,7,6]],"date-time":"2012-07-06T09:04:47Z","timestamp":1341565487000},"page":"117-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies"],"prefix":"10.1016","volume":"102","author":[{"given":"Antonio","family":"Gil-Nagel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin J.","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Cyr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Castiglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Twomey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevan","family":"VanLandingham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2012.05.007_bib0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1059-1311(02)00292-3","article-title":"An open-label study of levetiracetam at individualised doses between 1000 and 3000mgday\u22121 in adult patients with refractory epilepsy","volume":"12","author":"Abou-Khalil","year":"2003","journal-title":"Seizure"},{"issue":"Suppl. 181","key":"10.1016\/j.eplepsyres.2012.05.007_bib0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0404.2005.00504.x","article-title":"Data from regulatory studies: what do they tell? What don\u2019t they tell?","volume":"112","author":"Ben-Menachem","year":"2005","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2012.05.007_bib0015","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1528-1167.2012.03441.x","article-title":"The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels","volume":"53","author":"Brickel","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2012.05.007_bib0020","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1212\/WNL.0b013e3181fd6170","article-title":"Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy","volume":"75","author":"Brodie","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2012.05.007_bib0025","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.0b013e3182194bd3","article-title":"Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy","volume":"76","author":"French","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2012.05.007_bib0030","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1059-1311(03)00047-5","article-title":"Measuring the efficacy of antiepileptic drugs","volume":"12","author":"Mohanraj","year":"2003","journal-title":"Seizure"},{"issue":"Suppl. 4","key":"10.1016\/j.eplepsyres.2012.05.007_bib0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-1331.2005.01327.x","article-title":"Defining success in clinical trials \u2013 profiling pregabalin, the newest AED","volume":"12","author":"Ryvlin","year":"2005","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.eplepsyres.2012.05.007_bib0040","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1468-1331.2009.02916.x","article-title":"Pregabalin in partial seizures: a pragmatic 21-week, open-label study (PREPS)","volume":"17","author":"Ryvlin","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.eplepsyres.2012.05.007_bib0045","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0031-6997(24)01469-8","article-title":"Potassium channels: molecular defects, diseases, and therapeutic opportunities","volume":"52","author":"Shieh","year":"2000","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.eplepsyres.2012.05.007_bib0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.eplepsyres.2007.06.002","article-title":"The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy","volume":"76","author":"Steinhoff","year":"2007","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2012.05.007_bib0055","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1528-1167.2010.02532.x","article-title":"Long-term add-on pregabalin treatment in patients with partial-onset epilepsy: pooled analysis of open-label clinical trials","volume":"51","author":"Uthman","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2012.05.007_bib0060","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1528-1157.1999.tb02017.x","article-title":"The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy","volume":"40","author":"Wong","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2012.05.007_bib0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1600-0404.2008.01055.x","article-title":"Long-term safety and efficacy of zonisamide in patients with refractory partial-onset epilepsy","volume":"118","author":"Wroe","year":"2008","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2012.05.007_bib0070","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1124\/mol.104.010793","article-title":"The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate","volume":"67","author":"Wuttke","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2012.05.007_bib0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0404.2006.00705.x","article-title":"Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies?","volume":"114","author":"Zaccara","year":"2006","journal-title":"Acta Neurol. Scand."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121112001635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121112001635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:27:41Z","timestamp":1760275661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121112001635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":15,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0920121112001635"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2012.05.007","relation":{},"ISSN":["0920-1211"],"issn-type":[{"type":"print","value":"0920-1211"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2012.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}